Tikosyn shortage over
Executive Summary
Pfizer is sending "Dear Healthcare Professional" letters alerting physicians that shortages for its atrial fibrillation/atrial flutter therapy Tikosyn are resolved, the company announces Feb. 1. The outages for 0.25 mg and 0.5 mg doses of dofetilide resulted from manufacturing issues that do not impact Tikosyn's safety or efficacy, Pfizer states...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.